Olanzapine for Huntington's disease: An open label study

Clinical Neuropharmacology

Volumn 25, Issue 5, 2002, Pages 263-265

  Bonelli, Raphael M ^a   Mahnert, Franz A ^a   Niederwieser, Gerald ^a  

^a Hospital BHB Eggenberg   (Austria)

Author keywords

Chorea; Huntington's disease; Neuroleptics; Olanzapine

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MEGADOSE; DRUG TOLERANCE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; MOTOR PERFORMANCE; NERVE DEGENERATION; PARKINSONISM; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RISK ASSESSMENT; SIDE EFFECT; TASK PERFORMANCE;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PIRENZEPINE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036709253     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-200209000-00007     Document Type: Article

References (18)

1. Barr AN, Fischer JH, Koller WC, et al. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988;38:84-8.
2. Arena R, Iudice A, Virgili P, et al. Huntington's disease: clinical effects of a short-term treatment with pimozide. Adv Biochem Psychopharmacol 1980;24:573-5.
3. Terrence CF. Fluphenazine decanoate in the treatment of chorea: A double-blind study. Curr Ther Res Clin Exp 1976;20:177-83.
4. Dipple HC. The use of olanzapine for movement disorder in Huntington's disease: A first case report. J Neurol Neurosurg Psychiatry 1999;67:123-4.
5. Etchebehere EC, Lima MC, Passos W, et al. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine. Case report. Arq Neuropsiquiatr 1999;57:863-6.
6. Grove VE, Jr., Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000;343:973-4.
7. Bogelman G, Hirschmann S, Modai I. Olanzapine and Huntington's disease. J Clin Psychopharmacol 2001;21:245-6.
8. Squitieri F, Cannella M, Piorcellini A, et al. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:69-72.
9. Bonelli RM, Niederwieser G, Tribl GG, et al. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol 2002;17:91-3.
10. Bonelli RM, Niederwieser G, Diez J, et al. Riluzole and olanzapine in Huntington's disease. Eur J Neurol 2002;9:183-4.
11. Shoulson I, Fahn S. Huntington disease: Clinical care and evaluation. Neurology 1979;29:1-3.
12. Group HS. Unified Huntington's disease rating scale: Reliability and consistency. Mov Disord 1996;11:136-42.
13. Bonelli RM, Thau K. Noncompliance: Ein überblick. Dtsch Med Wochenschr 2001;126:699-703.
14. Folstein SE, Jensen B, Leigh RJ, et al. The measurement of abnormal movement: Methods developed for Huntington's disease. Neurobehav Toxicol Teratol 1983;5:605-9.
15. Dursun SM, Burke JG, Andrews H, et al. The effects of antipsychotic medication on saccadic eye movement abnormalities in Huntington's disease. Prog Neuropsychopharmacol Biol Psychiatry 2000;24:889-96.
16. Churchyard AJ, Morris ME, Georgiou N, et al. Gait dysfunction in Huntington's disease: Parkinsonism and a disorder of timing. Implications for movement rehabilitation. Adv Neurol 2001;87:375-85.
17. Smith MA, Brandt J, Shadmehr R. Motor disorder in Huntington's disease begins as a dysfunction in error feedback control. Nature 2000;403:544-9.
18. van Vugt JP, Siesling S, Vergeer M, et al. Clozapine versus placebo in Huntington's disease: A double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997;63:35-9.